Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the companies behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 140,000 members, many of whom demonstrate better investing insight than published analysts do.
After falling back to a four-star rank, where it sat for the past several months, Teva Pharmaceutical
Many CAPS members see a big future ahead for generic drugs in general and think they will play a big part in saving health-care costs. Many drugmakers like Pfizer
Its multiple sclerosis drug Copaxone faces a generic threat of its own coming from Mylan
Do you think Teva Pharmaceutical deserves its five-star status? Add your thoughts in the comments box below on this page, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.
Fool contributor Dave Mock has considered upgrading his workout with performance-enhancing water but is skeptical of its true impact. He owns shares Pfizer, which is also an Inside Value selection. Novartis is a Global Gains recommendation. Momenta is a Rule Breakers recommendation. The Fool's disclosure policy has many generic knockoffs that don't even come close to its performance.